BIT Capital GmbH Purchases New Shares in COMPASS Pathways plc (NASDAQ:CMPS)

BIT Capital GmbH bought a new position in COMPASS Pathways plc (NASDAQ:CMPS) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 115,697 shares of the company’s stock, valued at approximately $437,000.

Other hedge funds have also added to or reduced their stakes in the company. Sio Capital Management LLC raised its holdings in COMPASS Pathways by 211.7% during the 3rd quarter. Sio Capital Management LLC now owns 914,639 shares of the company’s stock worth $5,762,000 after buying an additional 621,222 shares during the period. Polar Asset Management Partners Inc. boosted its position in COMPASS Pathways by 83.3% during the third quarter. Polar Asset Management Partners Inc. now owns 567,600 shares of the company’s stock worth $3,576,000 after purchasing an additional 258,000 shares during the period. Acuta Capital Partners LLC bought a new stake in shares of COMPASS Pathways during the third quarter worth approximately $2,435,000. Walleye Capital LLC bought a new stake in shares of COMPASS Pathways in the third quarter valued at about $2,126,000. Finally, Franklin Resources Inc. boosted its stake in shares of COMPASS Pathways by 4.4% in the third quarter. Franklin Resources Inc. now owns 295,785 shares of the company’s stock valued at $1,810,000 after buying an additional 12,599 shares during the period. Institutional investors own 46.19% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on CMPS shares. Canaccord Genuity Group decreased their price objective on shares of COMPASS Pathways from $23.00 to $15.00 and set a “buy” rating on the stock in a research note on Friday, February 28th. Royal Bank of Canada reiterated an “outperform” rating and set a $18.00 target price on shares of COMPASS Pathways in a research report on Wednesday, January 15th. HC Wainwright reiterated a “buy” rating and issued a $45.00 price target on shares of COMPASS Pathways in a research report on Tuesday, March 4th. Finally, Stifel Nicolaus initiated coverage on shares of COMPASS Pathways in a research note on Thursday, February 27th. They set a “buy” rating and a $11.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $21.83.

COMPASS Pathways Trading Down 2.9 %

Shares of COMPASS Pathways stock opened at $2.98 on Thursday. The company’s 50-day moving average price is $3.88 and its 200-day moving average price is $4.77. The company has a current ratio of 8.91, a quick ratio of 8.91 and a debt-to-equity ratio of 0.15. COMPASS Pathways plc has a 12-month low of $2.85 and a 12-month high of $10.31. The company has a market cap of $276.17 million, a price-to-earnings ratio of -1.35 and a beta of 2.29.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Thursday, February 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.01). On average, equities analysts expect that COMPASS Pathways plc will post -2.33 earnings per share for the current fiscal year.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.